Literature DB >> 3048637

Steroid hormones and medications that alter cancer risks.

D B Thomas1.   

Abstract

Alkylating agents have caused acute nonlymphocytic leukemia (ANLL), probably bladder cancer, and possibly other solid tumors. Phenacetin also has enhanced risk of bladder cancer, and probably also carcinoma of the renal pelvis. Topical nitrogen mustard, potassium arsenite, tar ointments, and methoxsalene have been related to development of nonmelanotic skin cancers. Immunosuppression by azathioprine, usually with prednisone, has enhanced risks of non-Hodgkin's lymphomas, hepatobiliary cancers, and various mesenchymal tumors. Liver cancers have been reported in users of androgenic anabolic steroids, and both hepatic cell adenomas and carcinomas have been associated with use of combined oral contraceptives. These contraceptives reduce risks of endometrial and ovarian carcinomas. Estrogens increase risk of endometrial cancer. Exposure to diethylstilbestrol in utero can result in clear cell carcinomas of the vagina and cervix, and possibly testicular carcinomas.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3048637     DOI: 10.1002/1097-0142(19881015)62:1+<1755::aid-cncr2820621312>3.0.co;2-5

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  Establishment and characterization of a new human cell line (EJ) derived from endometrial carcinoma.

Authors:  Keiichi Isaka; Hirotaka Nishi; Toshihide Nakada; Yumi Osakabe; Mitsuyasu Hokamura; Hiromi Serizawa; Yoshiro Ebihara; Masaomi Takayama
Journal:  Hum Cell       Date:  2002-12       Impact factor: 4.174

2.  Dose and time-course evaluation of a redox-based estradiol-chemical delivery system for the brain. I. Tissue distribution.

Authors:  M H Rahimy; J W Simpkins; N Bodor
Journal:  Pharm Res       Date:  1990-10       Impact factor: 4.200

3.  Establishment and characterization of novel human primary endometrial cancer cell line (ZJB-ENC1) and its genomic characteristic.

Authors:  Xiaozhen Liu; Zhuozhuo Ren; Yu Xu; Wei Sun; Yongfeng Li; Xinmiao Rui; Dafei Xie; Xuli Meng; Zhiguo Zheng
Journal:  J Cancer       Date:  2019-10-20       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.